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Abstract
Background: HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV
infection, has been implicated in HAART-associated cardiovascular complications. Our previous studies have demonstrated
that activation of endoplasmic reticulum (ER) stress is linked to HIV PI-induced inflammation and foam cell formation in
macrophages. Raltegravir is a first-in-its-class HIV integrase inhibitor, the newest class of anti-HIV agents. We have recently
reported that raltegravir has less hepatic toxicity and could prevent HIV PI-induced dysregulation of hepatic lipid
metabolism by inhibiting ER stress. However, little information is available as to whether raltegravir would also prevent HIV
PI-induced inflammatory response and foam cell formation in macrophages.
Methodology and Principal Findings: In this study, we examined the effect of raltegravir on ER stress activation and lipid
accumulation in cultured mouse macrophages (J774A.1), primary mouse macrophages, and human THP-1-derived
macrophages, and further determined whether the combination of raltegravir with existing HIV PIs would potentially
exacerbate or prevent the previously observed activation of inflammatory response and foam cell formation. The results
indicated that raltegravir did not induce ER stress and inflammatory response in macrophages. Even more interestingly, HIV
PI-induced ER stress, oxidative stress, inflammatory response and foam cell formation were significantly reduced by
raltegravir. High performance liquid chromatography (HPLC) analysis further demonstrated that raltegravir did not affect the
uptake of HIV PIs in macrophages.
Conclusion and Significance: Raltegravir could prevent HIV PI-induced inflammatory response and foam cell formation by
inhibiting ER stress. These results suggest that incorporation of this HIV integrase inhibitor may reduce the cardiovascular
complications associated with current HAART.
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are two major risk factors of cardiovascular complications in HIV
patients under HAART.
Previous studies from other laboratories and ours suggest that
HIV PI-induced endoplasmic reticulum (ER) stress response and
subsequent activation of the unfolded protein response (UPR)
represent an important cellular signaling mechanism of HIV PIinduced metabolic syndromes (dyslipidemia, insulin-resistance,
lipodystrophy/lipoatrophy) [1,2,4–9]. ER stress has been closely
linked to various human diseases including inflammatory diseases,
cardiovascular diseases, diabetes, and all types of human liver
diseases [10]. Our previous in vitro studies have demonstrated that

Introduction
The development of HIV protease inhibitors (HIV PIs) is one of
the most significant advances of the past two decades in controlling
HIV infection. Incorporation of HIV PIs in HAART has had a
profound impact on the natural history of HIV and AIDS.
However, in the era of HAART, drug-induced metabolic toxicity
has emerged as an important complication of combination
antiretroviral therapy, particularly of those regimens containing
HIV PIs [1–3]. HIV PI-induced dyslipidemia and inflammation
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dimethyl sulfoxide (DMSO) and added directly to culture medium
(final concentrations 5 to 25 mM) and incubated for 0.5 to 24 h.
For each result, a minimum of three independent experiments was
performed. Cell viability was assessed with the Cellometer Vision
CBA Analysis System (Nexcelom Bioscience, Lawrence, MA) and
with the use of trypan blue.

most HIV PIs not only induce the accumulation of intracellular
free cholesterol and lipid and activate the UPR in hepatocytes and
macrophages, but they also increase the release of inflammatory
cytokines, promote foam cell formation and induce cell apoptosis
in macrophages [5,6].
HIV integrase inhibitor is a new class of antiviral agents used to
treat HIV-1-infected patients. Raltegravir (also known as
MK0518, Isentress) is a first-in-its-class oral integrase inhibitor
and has demonstrated potent efficacy against multidrug-resistant
HIV-1 and was initially approved by the FDA in 2007 to treat
treatment-experienced HIV-1-infected patients [11]. Recently,
raltegravir in combination treatment was listed as one of the
preferred regimens recommended for treatment-naive HIV-1infected patients. Clinical studies have shown that raltegravir was
well-tolerated and had fewer side effects compared to other classes
of antiretroviral drugs, such as HIV PIs and reverse transcriptase
inhibitors [12–14]. Our recent study demonstrated that raltegravir
is able to prevent HIV PI-induced dysregulation of hepatic lipid
metabolism by inhibiting the ER stress response [15]. However,
little information is available as to whether raltegravir would have
a similar protective effect against HIV PI-induced inflammatory
response and dysregulation of lipid metabolism in macrophages.
The current study was aimed at examining the effect of raltegravir
on HIV PI-induced inflammatory response, foam cell formation
and dysregulation of lipid metabolism in macrophages, and further
determining whether the combination of this integrase inhibitor
with existing, most commonly used HIV PIs (lopinavir and
ritonavir) could potentially prevent the previously observed
development of inflammatory response and foam cell formation.

Isolation and Culture of Primary Mouse Kupffer Cells and
Mouse Peritoneal Macrophages
Primary mouse Kupffer cells were isolated from male C57BL/6
mice (male 8-week old) using a Percoll gradient centrifugation
method as described previously by Jacob, et al [16]. Isolated
mouse Kupffer cells were cultured in DMEM supplemented with
10% FBS, 20% L-cell media, 100 U/ml penicillin, and 100 mg/ml
streptomycin at 37uC with 5% CO2. In order to isolate primary
mouse peritoneal macrophages, adult male C57BL/6 mice were
injected intraperitoneally with 0.5 ml of phosphate-buffered saline
(PBS) containing 40 mg of concanavalin A. The macrophages were
harvested 72 h after injection by peritoneal lavage. The harvested
cells were cultured in DMEM containing 10% fetal bovine serum
(FBS) and 20% L-cell-conditioned medium [6]. The medium was
replaced every 24 h until the macrophages were confluent. Animal
studies were approved by Institutional Animal Care and Use
Committee of Virginia Commonwealth University and were
conducted in accordance with the Declaration of Helsinki, the
Guide for the Care and Use of Animals (National Academy Press,
Washington, D.C., 1996), and all applicable regulations.

High-performance Liquid Chromatography (HPLC)
Analysis of Intracellular Uptake of HIV PIs and Raltegravir
in Macrophages

Methods

Mouse J774A.1 macrophages were treated with HIV PIs and
raltegravir (0 to 25 mM) for various time periods (0 to 24 h). The
culture medium and total cell lysates of each time point were
collected. The drugs in media and cells were extracted using solid
phase C-18 cartridges as described previously [5]. An Agilent 1200
Series HPLC system and a ZORBAX eclipse C18 reverse phase
column (5 mm, 4.6 mm625 cm, Agilent Technologies, Santa
Clara, CA) were used to quantify the HIV PIs and raltegravir in
cells. The gradient mobile phase for raltegravir consisted of
acetonitrile (A) and 0.01% triethylamine (B) adjusted to pH 3.0 by
phosphoric acid. The starting mobile phase consisted of 40% A
and 60% B (vol/vol) and was switched to 70% A and 30% B at
4 min, then changed back to 40% A and 60% B (v/v) at 6 min.
The mobile phase was delivered at 1 ml/min. The fluorescence
detector was used to detect raltegravir using excitation/emission
wavelengths of 299/396 nm [17]. The mobile phase for ritonavir
and lopinavir was acetonitrile: 20 mM sodium dihydrogenphosphate, pH 6 [60:40(v/v)] and 0.025% triethylamine. The mobile
phase was delivered at 1 ml/min. The peaks of ritonavir and
lopinavir were detected at 210 nm. A standard curve of each drug
was constructed using weighted linear regression of peak area ratio
values of the calibration standards. The percentage of drug
recovery after the solid-phase extraction was determined by
comparing the extracted internal standard.

Materials
Antibodies against C/EBP homologous protein (CHOP),
activating transcription factor-4 (ATF-4), X-box-binding protein1 (XBP-1), lamin B, horseradish peroxidase (HRP)-conjugated
donkey anti-goat IgG and HRP-conjugated goat anti-rabbit IgG
were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal antibody against b-actin was from Calbiochem (San
Diego, CA). Mouse monoclonal antibody against CD36 was from
Cayman Chemical (Ann Arbor, MI). Rabbit polyclonal antibody
against scavenger receptor A (SRA) was from R&D Systems
(Minneapolis, MN). Acetylated-LDL and oxidized-LDL were from
Intracel (Frederick, MD). Carboxy-DCFDA and carboxyH2DCFDA were from Invitrogen (Grand Island, NY). Bio-Rad
protein assay reagent, Criterion XT Precast Gel and Precision Plus
Protein Kaleidoscope Standards were obtained from Bio-Rad
(Hercules, CA). Kits for total cholesterol, free cholesterol, and
triglyceride were from Wako (Richmond, VA). Total RNA
isolation kit was from Promega (Madison, WI). High-capacity
cDNA archive kit was from Applied Biosystems (Foster City, CA).
All other chemical reagents were from Sigma (St. Louis, MO).

Cell Culture
Mouse J774A.1 macrophages (ATCC, Rockville MD, USA)
were maintained in DMEM supplemented with 10% FBS, 100 U/
ml penicillin, and 100 mg/ml streptomycin at 37uC with 5% CO2.
Cells from passages six to nine were used in these studies. Human
THP-1 monotypic cells (ATCC, Rockville MD, USA) were
cultured in RPMI 1640 medium supplemented with 10% FBS,
100 U/ml penicillin, and 100 mg/ml streptomycin at 37uC with
5% CO2. THP-1 monocytes were treated with PMA (100 ng/ml)
for 5 days to facilitate differentiation into macrophages. HIV PIs
(ritonavir and lopinavir) and Raltegravir were dissolved in
PLOS ONE | www.plosone.org

Enzyme-linked Immunosorbent Assays (ELISA) of
Cytokines
Mouse J774A.1 macrophages were treated with HIV PIs with or
without raltegravir for 24 h. At the end of the treatment, the
culture media were collected and centrifuged at 14,0006rpm for
5 min. The supernatants were stored in aliquots at 270uC. TNF-a
and IL-6 levels in the media were determined by ELISA using
2
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mouse TNF-a and mouse IL-6 ELISA MaxTM Set Deluxe Kits
(BioLegend). The total protein concentrations of the viable cell
pellets were determined using Bio-Rad Protein Assay reagent.
Total amounts of the TNF-a and IL-6 in media were normalized
to the total protein amounts of the viable cell pellets.

twice. The intracellular levels of total cholesterol, free cholesterol,
triglyceride, were measured using free cholesterol, cholesterol E
and triglyceride assay kits (Wako Bioproducts, Richmond, VA)
and normalized by total protein amount as described previously
[15].

Analysis of Apoptosis by Annexin V and Propidium
Iodide Staining

Assay of Endoplasmic Reticulum Calcium Pools
Mouse J774A.1 macrophages were grown on 22640-mm
coverslips and treated with vehicle or ritonavir with or without
raltegravir for 24 h. The cells were loaded with 4 mM Fura-2 AM
and 0.3% Plurinic F-127 in HBSS at 37uC for 60 min and
incubated in HBSS for an additional 30 min, then mounted on the
stage of an Axioskop 2 plus upright fluorescence microscope (Carl
Zeiss GmbH, Jena, Germany) equipped with a 406objective.
After washing with HBSS without Ca2+ and Mg2+ three times, the
cells were stimulated with 100 nM thapsigargin (TG) to induce the
calcium release from ER. Fluorescence images (510-nm emission
after alternate 340- and 380-nm excitation) before and after
addition of TG were collected at 15-ms intervals through a cooled
charge-coupled device camera (TILL Photonics LLC, Martinsreid,
Germany) which is attached to an image intensifier (VS4-1845;
Videoscope, Washington, DC), an epifluorescent light source
(Polychrome IV; TILL Photonics), a 515 nm dichroic beam
splitter, and a 535 nm emission filter (20 nm band pass; Omega
Optical, Brattleboro, VT). The 340:380 ratios of individual cells in
these images were analyzed using TILLvisION version 3.1
imaging software [6].

Mouse J774A.1 cells or human THP-1-derived macrophages
were treated with HIV PIs with or without raltegravir (25 mM) for
24 h and stained with Annexin V-FITC and propidium iodide
using BD ApoAlert Annexin V kit, according to the protocol
recommended by the manufacturer. Annexin V/propidium
iodide-stained cells were visualized under fluorescence microscopy
with a 406objective using a dual-filter set for FITC and
rhodamine [5,6]. The relative fluorescence density was determined
using IPLab 4.0 software.

Western Blot Analysis
The nuclear and cytosolic proteins were prepared as previously
described [5]. The protein concentration was determined using the
Bio-Rad protein assay reagent. The nuclear extracts (30 mg of
protein) or cytosol extracts (70 mg of protein) or total cell lysate
proteins (80 mg) were resolved on 10% or 7% or 12% Bis-Tris
NuPAGE Novex gels or 10% Criterion XT precast gels and
transferred to nitrocellulose membranes. Immunoblots were
blocked overnight at 4uC with 5% non-fat milk in TBS buffer
and incubated with primary antibodies. Immunoreactive bands
were detected using horseradish peroxidase–conjugated secondary
antibody and the Western Lightning Chemiluminescence Reagent
Plus. The density of the immunoblot bands was analyzed using
Imagelab software (Biorad, CA).

Measurement of Reactive Oxygen Species (ROS) by Flow
Cytometry
ROS production was detected in mouse J774A.1 cells loaded
with C-H2DCFDA-AM (Invitrogen), which was hydrolyzed by
intracellular esterases and oxidized to fluorescent carboxy-DCF
(excitation 488 nm; emission 525 nm), primarily by H2O2 in the
presence of peroxidase. Cells were treated with HIV PI with or
without raltegravir for 24 h, and then incubated with CH2DCFDA-AM (5 mM) for 30 min (37uC). Cells without dye
were used as negative control and H2O2 treated cells were used as
a positive control. Cells were collected and washed with PBS. Cells
were analyzed by flow cytometry using a Beckman Coulter
(EPICS XL). In order to determine the effect of HIV PIs and
raltegravir on dye uptake in macrophages, J774A.1 cells were
loaded with the cell-permanent, oxidized form of the dye
(DCFDA-AM, 5 mM) and treated with HIV PIs with or without
raltegravir for 4 h. The fluorescence intensity was measured using
a 96-well plate reader.

Real-time Quantitative PCR
Total cellular RNA was isolated after treatment with HIV PIs
and raltegravir, or vehicle control (DMSO) for 24 h, using the
Promega SV Total RNA Isolation System. Total RNA (2 mg) was
used for the first-strand cDNA synthesis using the High-Capacity
cDNA Archive Kit. The mRNA levels of CHOP, spliced form of
XBP-1 (sXBP-1), ATF-4, CD36, scavenger receptor A (SRA),
ATP-binding cassette transporter A1 (ABCA1), and ABCG1 were
quantified using specific primers for each gene (Table 1). iQTM
SYBR Green Supermix (Bio-Rad Laboratories) was used as a
fluorescent dye to detect the presence of double-stranded DNA.
The mRNA values for each gene were normalized to internal
control b-actin mRNA. The ratio of normalized mean value for
each treatment group to vehicle control group was calculated.

Statistical Analysis
All results were expressed as mean 6 standard error of the
mean. One-way ANOVA and Student’s t test were used to analyze
the differences between different treatments. Statistics were
performed using GraphPad Pro. A probability (p) of less than
0.05 was considered statistically significant.

Oil Red O and Nile Red Staining
Cells were treated with HIV PIs with or without raltegravir for
24 h. Cells were fixed in 3.7% formaldehyde for 30 min. After
washing with PBS 3 times, the intracellular lipid was stained with
Oil Red O or Nile Red as described previously [6,18]. The images
were taken under 406lenses using an Olympus microscope
equipped with an image recorder. Images of Nile-Red staining
were obtained under a 406objective using a FITC filter on a
fluorescent microscope (Olympus, Center Valley, PA).

Results
Uptake of Raltegravir in Macrophages
In order to study the effect of raltegravir on HIV PI-induced
inflammation and dysregulation of lipid metabolism in macrophages, we first examined the uptake of raltegravir in macrophages. Mouse J774A.1 cells were incubated with raltegravir (25 mM)
for different time periods (0.5, 1, 2, 3, 4, 6, 12, and 24 h) or with
different amounts of raltegravir (10, 15, or 25 mM) for 0.5, 1, 2, 4
or 6 h. The intracellular drug concentrations of raltegravir were

Measurement of Intracellular Free Cholesterol, Total
Cholesterol and Triglyceride
Mouse J774A.1 macrophages were plated on 60-mm plates
overnight and then treated with control vehicle or HIV PIs for
24 h. At the end of the treatment, the cells were washed with PBS
PLOS ONE | www.plosone.org
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Table 1. Real time PCR primers.

Gene

Species

Gene bank Accession No

Forward Primer 59 to 39

Reverse Primer 59 to 39

ABCA1

Human

NM_005502

AGGCTGTGTCTCGTATTGTC

GAGTTGTAGAGTTGTCATAGAAGG

ABCG1

Human

NM_004915

CCGACCGACGACACAGAGA

GCACGAGACACCCACAAACC

ATF-4

Human

NM_001675

CAACAACAGCAAGGAGGATG

AATTGGGTTCACCGTCTGG

CD36

Human

NM_001001548

TGTCATTGGTGCTGTCCTG

TGTTGCTGCTGTTCATCATC

CHOP

Human

S40706

CTGAATCTGCACCAAGCATGA

AAGGTGGGTAGTGTGGCCC

IL-6

Human

NM_000600

CAGATTTGAGAGTAGTGAGGAAC

CGCAGAATGAGATGAGTTGTC

SRA

Human

NM_138715

TTCACAATCAACAGGAGGACAC

GCAAACACGAGGAGGTAAAGG

TNF-a

Human

NM_000594

CGAGTCTGGGCAGGTCTAC

GGGAGGCGTTTGGGAAGG

XBP-1s

Human

NM_005080

TCCGCAGCACTCAGACTAC

TCCAAGTTGTCCAGAATGCC

doi:10.1371/journal.pone.0090856.t001

determined by HPLC analysis. The results indicated that
raltegravir was rapidly and dose-dependently taken up by
macrophages (Fig. 1).

Effect of Raltegravir on HIV PI-induced UPR Activation
and Apoptosis
Our previous studies have shown that HIV PIs induce ER
stress, activate the UPR, and promote apoptosis in macrophages.
To determine whether raltegravir has a similar effect to HIV PIs
on ER stress activation and induction of apoptosis in macrophages, we treated the J774A.1 cells and human THP-1-derived
macrophages with raltegravir with or without ritonavir and
lopinavir. The expression of UPR marker genes CHOP, XBP-1,
and ATF-4 were determined by Western blot analysis. Thapsigargin, a known ER stress inducer, was used as a positive control.
The apoptotic and necrotic cells were stained using Annexin VFITC and Propidium Iodide and detected by fluorescence
microscopy as described previously [5,6]. As shown in Fig. 2,
raltegravir did not activate the UPR, but significantly reduced
HIV PI-induced expression of CHOP, XBP-1 and ATF-4 in
mouse macrophages. In addition, treatment of the cells with
raltegravir significantly prevented HIV PI-induced cell death
(Fig. 3A and B). Similarly, raltegravir did not induce cell apoptosis,
but it prevented HIV PI-induced cell apoptosis in human THP-1derived macrophages (Fig. 3C).

Effect of Raltegravir on HIV PI-induced Inflammatory
Response in Macrophages
We have previously shown that HIV PIs induce the expression
of proinflammatory cytokines (TNF-a and IL-6) in macrophages
[4]. To examine whether raltegravir has a similar effect as HIV PIs
on the expression of TNF-a and IL-6, J774A.1 cells were treated
with raltegravir with or without lopinavir and ritonavir. The
protein levels of TNF-a and IL-6 were determined by ELISA. As
shown in Fig. 4, raltegravir did not induce the expression of TNFa and IL-6, but significantly reduced HIV PI-induced expression
of TNF-a and IL-6. Similar results were obtained in human THP1 cell-derived macrophages (data not shown).

Figure 1. Time and dose-dependent uptake of raltegravir in
macrophages. (A). Mouse J774A.1 cells were treated with raltegravir
(25 mM) for various time periods (0.5, 1, 2, 3, 4 6, 12, and 24 h). At the
end of each treatment period, the cells were collected and intracellular
drug concentration was determined by HPLC and normalized with total
cellular protein amount as described in ‘‘Methods’’. The graphic
representation of intracellular drug levels over time is shown. (B).
Mouse J774A.1 cells were treated with different concentrations of
raltegravir (10, 15, and 25 mM) for various time periods (0.5, 1, 2, 4, and
6 h). The intracellular drug concentration was determined as described
above.
doi:10.1371/journal.pone.0090856.g001

Effect of Raltegravir on HIV PI-induced Foam Cell
Formation in Macrophages
Maintenance of the cellular lipid homeostasis is crucial to
various cellular functions. We have previously reported that HIV
PIs induce intracellular free cholesterol accumulation and foam
cell formation in macrophages [6]. To determine if the protective
PLOS ONE | www.plosone.org
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Figure 2. Effect of raltegravir on HIV PI-induced UPR activation in macrophages. (A). Mouse J774A.1 cells were treated with different
concentrations of raltegravir (0, 5, 15, 25 or 50 mM) in the absence or presence of ritonavir (RITV, 25 mM) or thapsigargin (TG, 100 nM), a known ER
stress inducer, for 4 h, and the nuclear proteins were isolated. Representative immunoblots from three independent experiments for CHOP, XBP-1,
ATF-4 and lamin B are shown. Lamin B was used as the loading control for nuclear proteins. (B). Human THP-1-derived macrophages were treated
with different concentrations of raltegravir (0, 5, 15, and 25 mM) in the absence or presence of lopinavir/ritonavir (LOPV/RITV, 25 mM) for 4 h.
Representative immunoblots from three independent experiments for CHOP, XBP-1, ATF-4 and lamin B are shown.
doi:10.1371/journal.pone.0090856.g002

further examined whether raltegravir had any effect on lopinavir
and ritonavir-induced foam formation in macrophages. Mouse
J774A.1 cells were loaded with acetylated-LDL or oxidized-LDL
and treated with HIV PIs with or without raltegravir for 24 h. The
intracellular lipid was stained using Oil Red O or Nile Red as
described previously [6,18]. As shown in Fig. 5, raltegravir did not
promote lipid accumulation in the presence of modified LDL, but

effect of raltegravir on HIV PI-induced UPR activation is
correlated to its effect on lipid homeostasis, we examined the
effect of HIV PIs on lipid accumulation in mouse primary Kupffer
cells and peritoneal macrophages. As shown in online supplementary Fig. S1, HIV PIs increased intracellular lipid accumulation.
Furthermore, our previous studies showed that HIV PIs induced
foam cell formation in human and mouse macrophages [6]. We

PLOS ONE | www.plosone.org
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Figure 3. Effect of raltegravir on HIV PI-induced apoptosis in macrophages. Mouse J774A.1 cells were treated with lopinavir (LOPV, 25 mM)
or ritonavir (RITV, 25 mM) with or without raltegravir (25 mM) for 24 h. At the end of treatment, the images of cells were taken using an Olympus
microscope equipped with an image recorder. Cell viability was assessed with the TC10 cell counter (BioRad) and with the use of trypan blue. (A).
Representative images of each treatment group. (B). Viable cell numbers from each treatment group. Values are mean 6 S.E. of three independent
experiments. ***, p,0.001, statistical significance relative to vehicle control. ###, p,0.001, statistical significance of HIV PI+raltegravir-treated
group relative to HIV PI-treated group. (C). Human THP-1-derived macrophages were treated with different concentrations of HIV PIs (15 or 25 mM),
lopinavir (LOPV), ritonavir (RITV) with or without raltegravir (25 mM) for 24 h. The apoptotic and necrotic cells were stained with Annexin V-FITC/
Propidium Iodide and monitored as described in ‘‘Methods’’. The representative images for each treatment are shown.
doi:10.1371/journal.pone.0090856.g003

reduced HIV PI-induced increase of lipid accumulation. Similar
results were obtained in human THP-1 cells (data not shown). We
further confirmed these observations in primary mouse peritoneal
macrophages. As shown in Fig. 6, raltegravir also reduced
lopinavir/ritonavir-induced uptake of oxidized-LDL and lipid
accumulation in primary mouse peritoneal macrophages. Our
previous studies have shown that ritonavir not only promoted the
foam cell formation, but it also increased the intracellular free

cholesterol accumulation in mouse macrophages [6]. In order to
determine whether raltegravir has any effect on HIV PI-induced
disruption of intracellular lipid homeostasis, we measured the
intracellular free cholesterol, total cholesterol and triglyceride
levels after the cells were treated with HIV PIs with or without
raltegravir. As shown in Fig. 7, raltegravir significantly reduced
lopinavir/ritonavir-induced increase of intracellular free cholesterol, total cholesterol and triglyceride in mouse J774A.1
macrophages. Similarly, lopinavir/ritonavir-induced increase of
intracellular free cholesterol, total cholesterol and triglyceride was
also inhibited by raltegravir in primary mouse peritoneal
macrophages (Fig. 8).

Effect of Raltegravir and HIV PIs on the Expression of Key
Genes Involved in Regulation of Lipid Homeostasis in
Macrophages
In order to identify the mechanisms by which raltegravir
prevents HIV PI-induced lipid accumulation in macrophages, we
first examined the effect of raltegravir and HIV PIs on the
expression of major surface receptors and transporters involved in
lipid homeostasis including ABCA1, ABCG1, CD36, SRA, and
LDLR in macrophages using real-time RT-PCR. As shown in
Fig. 9, similar to our previous findings in mouse macrophages,
HIV PIs (lopinavir/ritonavir) significantly increased the expression
of CD36, SRA and LDLR in human THP-1-derived macrophages, which was inhibited by raltegravir. However, HIV PIs and
raltegravir had no significant effect on the expression of ABCA1
and ABCG1 (data not shown).

Effect of Raltegravir on HIV PI-induced Depletion of ER
Calcium Stores in Macrophages
Maintenance of ER calcium homeostasis is essential for many
cellular functions. Disruption of ER calcium homeostasis is one of
the major cellular mechanisms of the UPR activation. We have
previously shown that HIV PI-induced ER stress activation is
closely linked to its effect on ER calcium store depletion. In order
to further determine whether raltegravir exerts its protective effect
against HIV PI-induced ER stress through regulating ER calcium
homeostasis in macrophages, we assessed the effect of raltegravir
on ritonavir-induced ER calcium depletion in J774A.1 cells using
the fluorescent calcium indicator fura-2/AM as described previously [6]. As shown in Fig. 10, raltegravir not only slightly
increased the ER calcium store by itself, but also prevented
ritonavir-induced reduction of ER calcium store.

Figure 4. Effect of raltegravir on HIV PI-induced TNF-a and IL-6
expression in macrophages. Mouse J774A.1 cells were treated with
HIV PIs (lopinavir/Ritonavir, 25 mM) with or without raltegravir (25 mM)
or vehicle control (DMSO) for 24 h. At the end of treatment, the culture
media and cells were collected separately. The amount of TNF-a and IL6 released into the media were analyzed by ELISA and normalized with
total protein amount of viable cells and expressed as pg/mg protein. (A).
TNF-a,***, p,0.001, statistical significance relative to vehicle control. #,
p,0.05, statistical significance of HIV PI+raltegravir-treated group
relative to HIV PI-treated group. (B). IL-6,***, p,0.001, statistical
significance relative to vehicle control. ##, p,0.01, statistical
significance of HIV PI+raltegravir-treated group relative to HIV PItreated group.
doi:10.1371/journal.pone.0090856.g004

PLOS ONE | www.plosone.org

Effect of Raltegravir on HIV PI-induced Oxidative Stress in
J774A.1 Cells
Numerous evidences indicate that ER stress activation is
associated with induction of oxidative stress. We further examined
the effect of raltegravir and HIV PIs on reactive oxygen species
(ROS) production in J774A.1 cells by flow cytometry using C-H2DCFDA as a fluorescent indicator. As shown in Fig. 11, ritonavir
significantly increased ROS production, which was inhibited by
raltegravir in a dose-dependent manner in macrophages. In order
7
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Figure 5. Effect of raltegravir on HIV PI-induced lipid accumulation in mouse J774A.1 macrophages. (A) J774A.1 cells were loaded with
Acetylated-LDL (50 mg/ml) and treated with 25 mM of LOPV, RITV, or vehicle control with or without raltegravir (25 mM) for 24 h. The intracellular lipid
was stained with Oil Red O as described under ‘‘Methods’’. The images were taken with the use of an Olympus microscope equipped with an image
recorder. The representative images are shown for each treatment group. (B). J774A.1 cells were loaded with oxidized-LDL (50 mg/ml) and treated
with 25 mM of LOPV/RITV (4:1), or vehicle control with or without raltegravir (25 mM) for 24 h. The intracellular lipid was stained with Nile Red as
described under ‘‘Methods’’. Images were obtained under a 406objective using a FITC filter on a fluorescent microscope. The representative images
are shown for each treatment group.
doi:10.1371/journal.pone.0090856.g005

PLOS ONE | www.plosone.org

8

March 2014 | Volume 9 | Issue 3 | e90856

HIV Integrase Inhibitor and ER Stress

Figure 6. Effect of raltegravir on HIV PI-induced lipid accumulation in primary mouse peritoneal macrophages. (A). Primary mouse
peritoneal macrophages were loaded with Acetylated-LDL (50 mg/ml) and treated with 25 mM of LOPV, RITV, or vehicle control with or without
raltegravir (25 mM) for 24 h. The intracellular lipid was stained with Oil Red O or Nile Red and images were taken as described under ‘‘Methods’’. (A).
The representative Oil Red O staining images are shown for each treatment group. (B). The representative Nile Red staining images are shown for
each treatment group.
doi:10.1371/journal.pone.0090856.g006

to exclude the possibility of HIV PI-induced increase of
intracellular fluorescence due to the increase of dye up-take, we
further examined the effect of HIV PIs and raltegravir on dye uptake using oxidized DCFDA. As shown in online supplementary
Fig. S2, raltegravir had no effect on dye uptake, however,
lopinavir/ritonavir significantly reduced dye up-take. These results

PLOS ONE | www.plosone.org

further suggest that HIV PIs significantly increased cellular
oxidative stress.

Discussion
HIV PIs have been successfully used in HAART for HIV
infection, which is the most effective treatment currently available.
9
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Figure 8. Effect of raltegravir on HIV PI-induced disruption of
lipid homeostasis in primary mouse peritoneal macrophages.
Mouse primary peritoneal macrophages were isolated as described in
‘‘Methods’’ and cultured for 48 h. Cells were treated with LOPV/RITV
(25 mM) in the presence or absence of raltegravir (25 mM) for 24 h. Total
cell lysates were used to measure the intracellular free cholesterol, total
cholesterol, and triglyceride using Wako kits and normalized using total
protein amount. The results are expressed as % of control. The values
are means 6 S.E. of three independent experiments. *, p,0.05; **, p,
0.01, statistical significance relative to vehicle control. #, p,0.05; ##,
p,0.01, statistical significance of LOPV/RITV+raltegravir-treated group
relative to LOPV/RITV-treated group.
doi:10.1371/journal.pone.0090856.g008

Figure 7. Effect of raltegravir on HIV PI-induced disruption of
lipid homeostasis in macrophages. Mouse J774A.1 cells were
treated with LOPV/RITV (15 mM) in the presence or absence of
raltegravir (15 mM) for 24 h. Total cell lysates were used to measure
the intracellular free cholesterol, total cholesterol, and triglyceride using
Wako kits and normalized using total protein amount. The values are
means 6 S.E. of three independent experiments. **, p,0.01, statistical
significance relative to vehicle control. #, p,0.05, statistical significance
of LOPV/RITV+raltegravir-treated group relative to LOPV/RITV-treated
group.
doi:10.1371/journal.pone.0090856.g007

PLOS ONE | www.plosone.org

10

March 2014 | Volume 9 | Issue 3 | e90856

HIV Integrase Inhibitor and ER Stress

Figure 9. Effect of raltegravir and HIV PIs on the expression of key genes involved in lipid transport in macrophages. (A–C) Human
THP-1-derived macrophages were treated with HIV PIs (lopinavir/Ritonavir, LOPV/RITV, 25 mM) with or without raltegravir (25 mM) for 24 h. The total
cellular RNA was isolated and reverse transcribed. The relative mRNA levels of CD36, SRA, and LDLR were determined by real-time PCR as described in
‘‘Methods’’. The values are means 6 S.E. of three independent experiments. **, p,0.01, ***, p,0.001, statistical significance relative to vehicle control.
#, p,0.05, statistical significance of HIV PI+raltegravir-treated group relative to HIV PI-treated group. (D) Human THP-1-derived macrophages were
treated with HIV PIs (lopinavir/Ritonavir, LOPV/RITV, 25 mM) with or without raltegravir (25 mM) for 24 h. The total protein lysates were prepared and
subjected to Western blot analysis. Representative immunoblots for CD36, SRA and b-actin are shown. b-actin was used as the loading control for
total proteins.
doi:10.1371/journal.pone.0090856.g009

In the present study, we examined the effects of raltegravir on
HIV PI-induced activation of ER stress, inflammation and
dysregulation of lipid metabolism in cultured macrophages and
mouse primary macrophages. The results demonstrated that
raltegravir has less toxicity and could prevent HIV PI-induced
ER stress activation, up-regulation of inflammatory cytokines, and
foam cell formation (Figs. 4–6).
The role of ER stress is a rapidly emerging field of interest in the
pathogenesis of various human diseases including liver diseases,
metabolic syndromes, diabetes, inflammatory bowel diseases, and
cardiovascular diseases [22–26]. Our previous studies demonstrated that activation of ER stress also plays a critical role in HIV PIinduced disruption of intestinal barrier integrity [27] and
dysregulation of hepatic lipid metabolism [5]. Our recent studies
have indicated that raltegravir could prevent HIV PI-induced
apoptosis and disruption of lipid metabolism by inhibiting ER
stress in rat primary hepatocytes and in liver [15]. In this study, we
further showed that raltegravir also inhibited HIV PI-induced ER
stress activation, apoptosis, and inflammatory response in macrophages.
The pathways of ER stress activation and lipid metabolism are
woven together tightly. Lipid overloading in macrophages is a
prerequisite for foam cell formation, which leads to the development
of atherosclerotic lesions. Accumulation of intracellular lipid results

However, the benefit of HAART is compromised by HIV PIinduced metabolic syndrome and cardiovascular complications
[2,3,7]. Until now, the underlying mechanisms behind serious
HIV PI-associated metabolic abnormality and atherosclerosis in
HIV-infected patients remain to be fully determined. Therapeutic
and preventive strategies have yielded only limited success so far.
Our previous studies and studies from other groups suggest that
HIV PI-induced ER stress activation represents a critical cellular
mechanism underlying HIV PI-induced inflammation, dyslipidemia, insulin resistance, and atherosclerosis [2,5,6,19,20]. It is well
recognized that macrophages play a pivotal role in regulating
inflammatory response and lipid metabolism.
Our recent studies indicated that raltegravir, the first agent in a
new class of antiretrovirals, HIV integrase inhibitors, is not only
less toxic, but also able to reduce HIV PI-induced dysregulation of
lipid metabolism by inhibiting the ER stress response [15]. Based
on the most recent guidelines for the use of antiretroviral agents in
HIV-1-infected adults and adolescents released by the United
States Department of Health and Human Services in February
2013, raltegravir has been listed as a component of the preferred
regimens recommended for treatment-naive HIV-1-infected patients. Clinical studies have shown that raltegravir is well-tolerated
with fewer side effects when compared to HIV PIs and reverse
transcriptase inhibitors [21].
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Figure 10. Effect of raltegravir on ritonavir-induced depletion of endoplasmic reticulum calcium stores in mouse macrophages.
Mouse J774A.1 cells were treated with ritonavir (25 mM) with or without raltegravir (25 mM) for 24 h. (A) Representative tracings of the Fura-2
fluorescence ratio of 340:380 nm in an individual macrophage for each treatment group before and after addition of 100 nM thapsigargin (TG) are
shown. (B) Relative calcium content was calculated by total area under the curve for each treatment group and expressed as a percentage of vehicle
control. Statistical significance relative to vehicle control, *, p,0.05; ***, p,0.001; Statistical significance relative to ritonavir group, ###,p,0.001.
doi:10.1371/journal.pone.0090856.g010

when lipid influx exceeds lipid degradation and export. Activation
of ER stress-mediated apoptosis will further increase the inflammatory response. Further analysis of the effect of raltegravir and
HIV PIs on the expression of major surface receptors responsible for
lipid uptake in macrophages suggested that raltegravir inhibited
HIV PI-induced foam cell formation mainly by down-regulating the

PLOS ONE | www.plosone.org

expression of CD36, SRA and LDLR (Fig. 9). It has been shown
that atherosclerosis is a chronic inflammatory disease and activation
of an inflammatory response is involved in all stages of atherosclerotic development [28]. We have previously shown that HIV PIinduced expression of inflammatory cytokines (TNF-a and IL-6) is
coupled to the UPR and ERK signaling pathways [4,6]. In this
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Figure 11. Effect of raltegravir on HIV PI-induced ROS production in macrophages. Mouse J774A.1 cells were treated with ritonavir (RITV,
15 mM) with or without raltegravir (10, or 15 mM) for 24 h, and then incubated with C-H2DCFDA-AM (2.5 mM) for 30 min (37uC). Cells without dye
were used as negative control. Cells treated with H2O2 (300 mM) were used as positive control. Cells were collected, washed with PBS and analyzed by
flow cytometry using a Beckman Coulter (EPICS XL). (A) The representative graphs for each treatment groups are shown. L and M represent the gates
for no fluorescence and high fluorescence, respectively. (B) The percent of cells with high fluorescence for each treatment group is shown. Statistical
significance relative to vehicle control, **, p,0.01; Statistical significance relative to ritonavir group, ##, p,0.01.
doi:10.1371/journal.pone.0090856.g011

may also prevent the uptake of modified lipids (oxidized LDL and
Ac-LDL) by macrophages. Recent studies also suggest that ER
stress and oxidative stress are also closely linked to autophagy,
which has been recently identified as a key player in lipid
metabolism [34]. Whether HIV PIs and raltegravir have any effect
on autophagy activity remains to be further elucidated and is our
current ongoing project.
In summary, the development of a HIV integrase inhibitor is a
major step in the recent advance of anti-HIV therapy. Raltegravir
not only increases the number of available agents to treat
multidrug-resistant HIV infection with fewer side effects, but also
provides a promising alternative in order to reduce the cardiovascular complications associated with commonly used anti-HIV
agents. Our previous studies and the preliminary observations
presented in this study suggest that HIV integrase inhibitors may

study, we found that raltegravir not only inhibited HIV PI-induced
UPR activation, but also inhibited HIV PI-induced ERK activation
(data not shown). Furthermore, raltegravir was able to reduce HIV
PI-induced oxidative stress as indicated by reduction of ROS
production in macrophages (Fig. 11). Activation of oxidative stress is
closely associated with ER stress activation and has been linked to
the pathogenesis of cardiovascular diseases and other inflammatory
diseases [29–31]. We also showed that HIV PIs induce ROS
production in cardiac myocytes [32].
Previous studies have shown that accumulation of intracellular
free cholesterol induces ER stress by depletion of ER calcium store
[33]. Our studies suggest that the raltegravir-mediated protective
effect against HIV PI-induced dysregulation of lipid metabolism
and activation of ER stress may act through the stabilization of the
ER calcium content. The inhibition of CD36 and SRA expression
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Effect of HIV PIs and raltegravir on fluorescent dye up-taking in mouse J774A.1 cells. J774A.1 cells
were loaded with the cell-permanent, oxidized form of the dye
(DCFDA-AM, 5 mM) and treated with lopinavir/ritonavir
(15 mM) with or without raltegravir (15 mM) for 4 h. The
fluorescence intensity was measured using a 96-well plate reader.
The values were means 6 S.E. of three independent experiments.
**, p,0.01, statistical significance relative to vehicle control.
(TIF)

be useful compounds not only for inhibiting multidrug-resistant
HIV, but also for preventing HIV PI-associated metabolic
complications. Our studies will provide important information
for optimizing the combinational therapeutic regimen for HIV
infection.

Figure S2

Supporting Information
Effect of raltegravir on HIV PI-induced lipid
accumulation in primary mouse macrophages. A. Primary mouse Kupffer cells were isolated from C57/BL6 wild type
mice and cultured for two days and then treated with LOPV/
RITV (15 mM) with or without raltegravir (15 mM) for 24 h. B.
Primary mouse peritoneal macrophages were isolated from C57/
BL6 wild type mice and cultured for three days and then treated
with LOPV/RITV (15 mM) with or without raltegravir (15 mM)
for 24 h. The intracellular lipid was stained with Oil Red O as
described under ‘‘Methods’’. The images were taken with the use
of an Olympus microscope equipped with an image recorder.
Representative images are shown for each treatment group.
(TIF)
Figure S1
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